It can be tricky putting a price tag on a biotech company, especially one that offers no profits but promises of big success …
Intellipharmaceutics International Inc. (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage …
hares of IntelliPharmaceutics International (NASDAQ: IPCI) saw a nearly 6% increase in trading on Tuesday, February 2nd following the company’s announcement that it has signed …
In a research report released September 5, Maxim Group analyst Jason Kolbert upgraded shares of IntelliPharmaCeutics (NASDAQ:IPCI) from Hold to Buy rating and raised his price target to $7.00 (from $3.
In a research report released July 21, Maxim Group analyst Jason Kolbert reaffirmed a Hold rating on IntelliPharmaCeutics (IPCI) with a $3 price target. The analyst commented: “IPCI reported the quarter last …
In a research report issued today, IntelliPharmaCeutics International Inc. (IPCI) was downgraded by analyst Jason Kolbert at Maxim Group from Buy to Hold.